Burning Rock Biotech (BNR) Q3 2025 earnings summary

Executive summary

• Achieved positive operating cash flow in 3Q25, reversing prior negative trends and marking a significant milestone toward profitability.

• Total revenues for 3Q25 were RMB 131.6 million (US$18.5 million), up 2.3% year-over-year, driven by strong pharma R&D services growth.

• Net loss narrowed to RMB16.8 million (US$2.4 million) from RMB35.7 million in Q3 2024.

• Gross profit margin improved to 75.1% in 3Q25, up 3.7 percentage points year-over-year, driven by product mix optimization and cost control.

• Presented significant clinical study results in therapy selection and early cancer detection, and received regulatory approval in Japan for a companion diagnostic system.

Financial highlights

• Pharma R&D services revenue surged 68.6% year-over-year to RMB42.0 million, offsetting declines in in-hospital and central laboratory channels.

• Gross profit for 3Q25 was RMB 98.8 million, up 8% year-over-year; gross profit margin reached 75.1%.

• Adjusted EBITDA loss narrowed to RMB (5.4) million in 3Q25 from RMB (16.6) million in 3Q24, showing a clear trend toward breakeven.

• Operating expenses were reduced by 13% year-over-year in 3Q25, with disciplined cuts across R&D, S&M, and G&A.

• Cash, cash equivalents, and restricted cash stood at RMB467.0 million (US$65.6 million) as of September 30, 2025.

Outlook and guidance

• Continued focus on driving profitability through efficiency gains, cost control, and revenue growth in overseas and biopharma segments.

• Expectation of further cost savings and improved sales efficiency going forward.

• Management highlighted ongoing transition to in-hospital testing and continued focus on high-margin pharma R&D projects.

• Forward-looking statements caution about risks and uncertainties due to market and operating conditions.